Cited by 4,506Cancer-related Molecular PathwaysHeat shock proteins researchUbiquitin and proteasome pathways

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mdm2 promotes the rapid degradation of p53

Haupt, Ygal, Maya, Ruth, Kazaz, Anat, Oren, Moshe·1997·Nature

Open this paper in CoChat — free account

Abstract

The p53 tumour-suppressor protein exerts antiproliferative effects, including growth arrest and apoptosis, in response to various types of stress. The activity of p53 is abrogated by mutations that occur frequently in tumours, as well as by several viral and cellular proteins. The Mdm2 oncoprotein is a potent inhibitor of p53. Mdm2 binds the transcriptional activation domain of p53 and blocks its ability to regulate target genes and to exert antiproliferative effects. On the other hand, p53 activates the expression of the mdm2 gene in an autoregulatory feedback loop. The interval between p53 activation and consequent Mdm2 accumulation defines a time window during which p53 exerts its effects. We now report that Mdm2 also promotes the rapid degradation of p53 under conditions in which p53 is otherwise stabilized. This effect of Mdm2 requires binding of p53; moreover, a small domain of p53, encompassing the Mdm2-binding site, confers Mdm2-dependent detstabilization upon heterologous proteins. Raised amounts of Mdm2 strongly repress mutant p53 accumulation in tumour-derived cells. During recovery from DNA damage, maximal Mdm2 induction coincides with rapid p53 loss. We propose that the Mdm2-promoted degradation of p53 provides a new mechanism to ensure effective termination of the p53 signal.

Integrity signals

Registry

Crossref · 10.1038/387296a0

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., & Howley, P. M. (1993) · Cell · doi:10.1016/0092-8674(93)90384-3 · Cited by 2,416
The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,089
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652
In vivo ubiquitination and proteasome-mediated degradation of p53(1).
Maki, C. G., Huibregtse, J. M., & Howley, P. M. (1996) · PubMed · Cited by 645
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603
Interaction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 483
Self-citation

Flagged first, then by citations

Show all 29 references

Sorted by citations

Items 901–1,000 of 1,057

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 101
The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models
Wang, W., Qin, J., Voruganti, S., Srivenugopal, K. S., Nag, S. A., Patil, S. A., Sharma, H., Wang, M., Wang, H., Buolamwini, J. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms6086 · Cited by 100
FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage
Chung, Y. M., Park, S., Tsai, W.-B., Wang, S., Ikeda, M.-A., Berek, J. S., Chen, D. J., & Hu, M. C. ‐. (2012) · Nature Communications · doi:10.1038/ncomms2008 · Cited by 104
Nano-hydroxyapatite and Nano-titanium Dioxide Exhibit Different Subcellular Distribution and Apoptotic Profile in Human Oral Epithelium
Tay, C. Y., Fang, W., Setyawati, M. I., Chia, S. L., Tan, K. S., Hong, C., & Leong, D. T. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am501266a · Cited by 101
Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.
Satyamoorthy, K., Chehab, N. H., Waterman, M. J. F., Lien, M. C., El‐Deiry, W. S., Herlyn, M., & Halazonetis, T. D. (2000) · PubMed · Cited by 98
Transcriptional regulation of cellular senescence
Lanigan, F., Geraghty, J. G., & Bracken, A. P. (2011) · Oncogene · doi:10.1038/onc.2011.34 · Cited by 95
The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells
Donati, G., Bertoni, S., Brighenti, E., Vici, M., Treré, D., Volarević, S., Montanaro, L., & Derenzini, M. (2011) · Oncogene · doi:10.1038/onc.2011.48 · Cited by 100
p53–Mdm2 loop controlled by a balance of its feedback strength and effective dampening using ATM and delayed feedback
Wagner, J., Ma, L., Rice, J. J., Hu, W., Levine, A. J., & Stolovitzky, G. A. (2005) · Systems Biology · doi:10.1049/ip-syb:20050025 · Cited by 95
Differential Regulation of Cardiomyocyte Survival and Hypertrophy by MDM2, an E3 Ubiquitin Ligase
Tóth, A., Nickson, P., Qin, L. L., & Erhardt, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509630200 · Cited by 97
Gadd45a contributes to p53 stabilization in response to DNA damage
Jin, S., Mazzacurati, L., Zhu, X., Tong, T., Song, Y., Shao, S., Petrik, K. L., Rajasekaran, B., Wu, M., & Zhan, Q. (2003) · Oncogene · doi:10.1038/sj.onc.1206907 · Cited by 99
Integrins regulate the apoptotic response to DNA damage through modulation of p53
Lewis, J. M., Truong, T., & Schwartz, M. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062698499 · Cited by 100
Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes
Masdehors, P., Merle‐Béral, H., Maloum, K., Ōmura, S., Magdelénat, H., & Delić, J. (2000) · Blood · doi:10.1182/blood.v96.1.269 · Cited by 98
p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment
Pan, Y., Oprysko, P. R., Asham, A. M., Koch, C. J., & Simon, M. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207657 · Cited by 98
MDM2: life without p53
Daujat, S., NEEL, H., & PIETTE, J. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02369-1 · Cited by 97
An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis
Steinman, H. A., Burstein, E., Lengner, C., Gosselin, J., Pihan, G., Duckett, C. S., & Jones, S. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305966200 · Cited by 96
p53 in neurodegenerative diseases and brain cancers
Checler, F., & da Costa, C. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.009 · Cited by 99
Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer
Duan, W., Gao, L., Druhan, L. J., Zhu, W., Morrison, C., Otterson, G. A., & Villalona-Calero, M. A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh292 · Cited by 96
A new p38 MAP kinase‐regulated transcriptional coactivator that stimulates p53‐dependent apoptosis
Cuadrado, A., Lafarga, V., Cheung, P., Dolado, I., Llanos, S., Cohen, P., & Nebreda, Á. R. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601657 · Cited by 101
Improving cancer therapy by non-genotoxic activation of p53
Laı́n, S., & Lane, D. P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00063-7 · Cited by 99
Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms.
Matsumoto, R., Tada, M., Nozaki, M., Zhang, C. L., Sawamura, Y., & Abe, H. (1998) · PubMed · Cited by 97
Cell cycle regulatory functions of the human oncoprotein MDM2.
Deb, S. P. (2003) · PubMed · Cited by 96
c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination
Vogt Sionov, R., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., & Haupt, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5869-5878.2001 · Cited by 94
Self-citation
The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant
Anil, B., Riedinger, C., Endicott, J., & Noble, M. E. M. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913004459 · Cited by 95
Degradation of mutant p53H175 protein by Zn(II) through autophagy
Garufi, A., Pucci, D., D’Orazi, V., Cirone, M., Bossi, G., Avantaggiati, M. L., & D’Orazi, G. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.217 · Cited by 97
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103
Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt–Mdm2–p53 pathway
Rogulski, K. R., Li, Y., Rothermund, K. D., Pu, L., Watkins, S. C., Yi, F., & Prochownik, E. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208897 · Cited by 96
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia
Saddler, C. M., Ouillette, P. D., Kujawski, L. A., Shangary, S. K., Talpaz, M., Kaminski, M. S., Erba, H. P., Shedden, K., Wang, S., & Malek, S. N. (2007) · Blood · doi:10.1182/blood-2007-09-112698 · Cited by 96
Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation
McCoy, M. A., Gesell, J. J., Senior, M. M., & Wyss, D. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0334477100 · Cited by 96
N‐acetylcysteine prevents nitric oxide‐induced chondrocyte apoptosis and cartilage degeneration in an experimental model of osteoarthritis
Nakagawa, S., Arai, Y., Mazda, O., Kishida, T., Takahashi, K. A., Sakao, K., Saito, M., Honjo, K., Imanishi, J., & Kubo, T. (2009) · Journal of Orthopaedic Research® · doi:10.1002/jor.20976 · Cited by 101
The N-Terminal Domain of p73 Interacts with the CH1 Domain of p300/CREB Binding Protein and Mediates Transcriptional Activation and Apoptosis
Zeng, X., Li, X., Miller, A., Yuan, Z.-M., Yuan, W., Kwok, R. P. S., Goodman, R. H., & Lu, H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1299-1310.2000 · Cited by 97
Role for p300 in Stabilization of p53 in the Response to DNA Damage
Yuan, Z.-M., Huang, Y., Ishiko, T., Nakada, S., Utsugisawa, T., Shioya, H., Utsugisawa, Y., Yokoyama, K. K., Weichselbaum, R. R., Shi, Y., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.1883 · Cited by 97
Nuclear degradation of p53 occurs during down‐regulation of the p53 response after DNA damage
Shirangi, T. R., Zaika, A., & Moll, U. M. (2002) · The FASEB Journal · doi:10.1096/fj.01-0617fje · Cited by 97
Identification of a DNA Damage–Induced Alternative Splicing Pathway That Regulates p53 and Cellular Senescence Markers
Chen, J., Crutchley, J., Zhang, D., Owzar, K., & Kastan, M. B. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0908 · Cited by 93
MDM2 and MDMX can interact differently with ARF and members of the p53 family
Wang, X., Arooz, T., Siu, W. Y., Chiu, C. H. S., Lau, A., Yamashita, K., & Poon, R. Y. C. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02124-x · Cited by 94
p53-Independent Effects of Mdm2
Bohlman, S., & Manfredi, J. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_13 · Cited by 98
β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders
van Gastel, J., Hendrickx, J. O., Leysen, H., Santos‐Otte, P., Luttrell, L. M., Martin, B., & Maudsley, S. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01369 · Cited by 98
Do Mutations Turn p53 into an Oncogene?
Pitolli, C., Wang, Y., Mancini, M., Shi, Y., Melino, G., & Amelio, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246241 · Cited by 97
The role of MDM2–p53 axis dysfunction in the hepatocellular carcinoma transformation
Cao, H., Chen, X., Wang, Z., Wang, L., Xia, Q., & Zhang, W. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0287-y · Cited by 93
The Bitter End
Patterson, C., Ike, C., Willis, P. W., Stouffer, G. A., & Willis, M. S. (2007) · Circulation · doi:10.1161/circulationaha.106.649863 · Cited by 95
CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus
Hernández, L., Beà, S., Pinyol, M., Ott, G., Katzenberger, T., Rosenwald, A., Bosch, F., López‐Guillermo, A., Delabie, J., Colomer, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1526 · Cited by 95
Siah-1 binds and regulates the function of Numb
Susini, L., Passer, B. J., Amzallag, N., Juven‐Gershon, T., Prieur, S., Privat, N., Tuynder, M., Gendron, M., Israël, A., Amson, R. B., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261571998 · Cited by 95
Self-citation
Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma
Møller, M. B., Ino, Y., Gerdes, A., Skøjdt, K., Louis, D., & Pedersen, N. (1999) · Leukemia · doi:10.1038/sj.leu.2401315 · Cited by 95
Nucleolar Proteins Suppress Caenorhabditis elegans Innate Immunity by Inhibiting p53/CEP-1
Fuhrman, L. E., Goel, A., Smith, J. P., Shianna, K. V., & Aballay, A. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000657 · Cited by 92
RETRACTED ARTICLE: Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
Daniele, S., Costa, B., Zappelli, E., Pozzo, E. D., Sestito, S., Nesi, G., Campiglia, P., Marinelli, L., Novellino, E., Rapposelli, S., et al. (2015) · Scientific Reports · doi:10.1038/srep09956 · Cited by 94
Retracted
Roles of ubiquitin signaling in transcription regulation
Hammond-Martel, I., Yu, H., & Affar, E. B. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.10.009 · Cited by 98
Cul4A Physically Associates with MDM2 and Participates in the Proteolysis of p53
Nag, A., Bagchi, S., & Raychaudhuri, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2598 · Cited by 94
The Human MDM2 Oncoprotein Increases the Transcriptional Activity and the Protein Level of the p53 Homolog p63
Calabrò, V., Mansueto, G., Parisi, T., Vivo, M., Calogero, R., & Mantia, G. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107173200 · Cited by 94
Mdm2 in the Response to Radiation
Perry, M. E. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.9.2.1 · Cited by 96
Murine Double Minute (MDM2) Blocks p53-coactivator Interaction, a New Mechanism for Inhibition of p53-dependent Gene Expression
Wadgaonkar, R., & Collins, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13760 · Cited by 97
hADA3 is required for p53 activity
Wang, T., Kobayashi, T., Takimoto, R., Denes, A. E., Snyder, E. L., El‐Deiry, W. S., & Brachmann, R. K. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6404 · Cited by 93
mdm2: a bridge over the two tumour suppressors, p53 and Rb
Yap, D., Hsieh, J.-K., Chan, F., & Lü, X. (1999) · Oncogene · doi:10.1038/sj.onc.1202954 · Cited by 93
Inhibition of p53‐dependent transcription by BOX‐I phospho‐peptide mimetics that bind to p300
Dornan, D., & Hupp, T. R. (2001) · EMBO Reports · doi:10.1093/embo-reports/kve025 · Cited by 93
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2
Xirodimas, D. P., Chisholm, J., Desterro, J. M. S., Lane, D. P., & Hay, R. T. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03310-0 · Cited by 94
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential
Montanaro, L., Treré, D., & Derenzini, M. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.006 · Cited by 98
Puma, noxa, p53, and p63 differentially mediate stress pathway induced apoptosis
Wang, J., Thomas, H. R., Li, Z., Yeo, N. C., Scott, H. E., Dang, N. D.-P., Hossain, M. I., Andrabi, S. A., & Parant, J. M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03902-6 · Cited by 98
New Immunohistochemical Markers in the Evaluation of Central Nervous System Tumors: A Review of 7 Selected Adult and Pediatric Brain Tumors
Takei, H., Bhattacharjee, M. B., Rivera, A. L., Dancer, Y., & Powell, S. Z.-E. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-234-nimite · Cited by 93
DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer
Wu, D.-W., Lee, M.-C., Wang, J., Chen, C.-Y., Cheng, Y.-W., & Lee, H. (2013) · Oncogene · doi:10.1038/onc.2013.107 · Cited by 95
Y-box factor YB1 controls p53 apoptotic function
Homer, C. R., Knight, D. A., Hananeia, L., Sheard, P. W., Risk, J. M., Lasham, A., Royds, J. A., & Braithwaite, A. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208998 · Cited by 93
Hypoxia attenuates the p53 response to cellular damage
Achison, M., & Hupp, T. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206434 · Cited by 93
Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization
Saxena, A. D., Rorie, C. J., Dimitrova, D. D., Daniely, Y., & Borowiec, J. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209714 · Cited by 94
Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities
Li, D. W.-C., Liu, J.-P., Schmid, P. C., Schlosser, R., Feng, H., Liu, W.-B., Yan, Q., Gong, L., Sun, S.-M., Deng, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209334 · Cited by 98
Ubiquitin, E6-AP, and Their Role in p53 Inactivation
Scheffner, M. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00003-5 · Cited by 93
Phosphatases in the cellular response to DNA damage
Freeman, A. K., & Monteiro, Á. N. A. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-27 · Cited by 104
MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia
Zhou, S., Gu, L., He, J., Zhang, H., & Zhou, M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06085-11 · Cited by 99
Polyamine depletion stabilizes p53 resulting in inhibition of normal intestinal epithelial cell proliferation
Li, L., Rao, J. N., Guo, X., Liu, L., Santora, R. J., Bass, B. L., & Wang, J. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.3.c941 · Cited by 93
Nuclear exclusion of p53 in a subset of tumors requires MDM2 function
Lu, W., Pochampally, R. R., Chen, L., Chomnawang, M. T., Wang, Y., & Chen, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203262 · Cited by 90
Involvement of the DNA Repair Protein hHR23 in p53 Degradation
Glockzin, S., Ogi, F.-X., Hengstermann, A., Scheffner, M., & Blattner, C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.8960-8969.2003 · Cited by 93
p53 and IGFBP-3: Apoptosis and Cancer Protection
Grimberg, A. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3008 · Cited by 96
Superinduction of CYP1A1 Gene Expression
Ma, Q., Renzelli, A. J., Baldwin, K. T., & Antonini, J. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12676 · Cited by 92
Distinct Regulation of p53 and p73 Activity by Adenovirus E1A, E1B, and E4orf6 Proteins
Steegenga, W. T., Shvarts, A., Riteco, N., Bos, J. L., & Jochemsen, A. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3885 · Cited by 93
Identification and Characterization of a Novel p300-mediated p53 Acetylation Site, Lysine 305
Wang, Y.-H., Tsay, Y.-G., Tan, B. C.-M., Lo, W.-Y., & Lee, S.-C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212574200 · Cited by 92
Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies
Molinaro, C., Martoriati, A., & Cailliau, K. (2021) · Cancers · doi:10.3390/cancers13153819 · Cited by 99
Loss of TRIM31 promotes breast cancer progression through regulating K48- and K63-linked ubiquitination of p53
Guo, Y., Li, Q., Zhao, G., Zhang, J., Yuan, H., Feng, T., Ou, D., Gu, R. C., Li, S., Li, K., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04208-3 · Cited by 95
BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network
Sun, X. S., Klingbeil, O., Lu, B., Wu, C., Ballon, C., Ouyang, M., Wu, X., Jin, Y., Hwangbo, Y., Huang, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05551-x · Cited by 96
Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage
Ozaki, T., Wu, D., Sugimoto, H., Nagase, H., & Nakagawara, A. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.127 · Cited by 92
Intra-uterine growth restriction is associated with increased apoptosis and altered expression of proteins in the p53 pathway in villous trophoblast
Heazell, A. E. P., Sharp, A. N., Baker, P. N., & Crocker, I. P. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0551-3 · Cited by 92
A Distinct p53 Protein Isoform Signature Reflects the Onset of Induction Chemotherapy for Acute Myeloid Leukemia
Ånensen, N., Oyan, A. M., Bourdon, J., Kalland, K. H., Bruserud, Ø., & Gjertsen, B. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1970 · Cited by 94
Hdm2 Recruits a Hypoxia-Sensitive Corepressor to Negatively Regulate p53-Dependent Transcription
Mirnezami, A., Campbell, S. J., Darley, M., Primrose, J. M., Johnson, P., & Blaydes, J. P. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00454-8 · Cited by 93
Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?
Yi, Y. W., You, K. S., Park, J., Lee, S., & Seong, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010048 · Cited by 100
TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)
Tornesello, M. L. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5448 · Cited by 105
p51A (TAp63γ), a p53 homolog, accumulates in response to DNA damage for cell regulation
Katoh, I., Aisaki, K., Kurata, S., Ikawa, S., & Ikawa, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203644 · Cited by 90
Apoptotic and Growth-Promoting Activity of E2F Modulated by MDM2
Loughran, Ö., & Thangue, N. B. L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.6.2186-2197.2000 · Cited by 90
Pathways of chemotherapy resistance in castration-resistant prostate cancer
Mahon, K. L., Henshall, S. M., Sutherland, R. L., & Horvath, L. G. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0343 · Cited by 89
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Stein, E. M., DeAngelo, D. J., Chromik, J., Chatterjee, M., Bauer, S., Lin, C.-C., Suárez, C., Vos, F. D., Steeghs, N., Cassier, P. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1295 · Cited by 91
Cell Cycle Regulation and p53 Activation by Protein Phosphatase 2Cα
Ofek, P., Ben‐Meir, D., Kariv-Inbal, Z., Oren, M., & Lavi, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211699200 · Cited by 89
Self-citation
RYBP stabilizes p53 by modulating MDM2
Chen, D., Zhang, J., Li, M., Rayburn, E. R., Wang, H., & Zhang, R. (2008) · EMBO Reports · doi:10.1038/embor.2008.231 · Cited by 89
DNA Damage-induced Inhibition of Securin Expression Is Mediated by p53
Zhou, Y., Mehta, K. R., Choi, A., Scolavino, S., & Zhang, X. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203793200 · Cited by 91
Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells
Kanovsky, M., Raffo, A. J., Drew, L., Rosal, R. V., Do, T., Friedman, F. K., Rubinstein, P., Visser, J. W. M., Robinson, R., Brandt‐Rauf, P. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211280698 · Cited by 90
The contribution of the acidic domain of MDM2 to p53 and MDM2 stability
Argentini, M., Barboule, N., & Wasylyk, B. (2001) · Oncogene · doi:10.1038/sj.onc.1204241 · Cited by 90
Regulation and activation of p53 and its family members
Lohrum, M. A. E., & Vousden, K. H. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400625 · Cited by 91
Degradation of transcription factor IRF‐1 by the ubiquitin–proteasome pathway
Nakagawa, K., & Yokosawa, H. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01163.x · Cited by 92
Role of p53 in the progression of gastric cancer
Busuttil, R. A., Zapparoli, G. V., Haupt, S., Fennell, C. M., Wong, S. Q., Pang, J., Takeno, E. A., Mitchell, C., Costanzo, N. D., Fox, S. B., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2434 · Cited by 89
Self-citation
The role of ubiquitin ligases in cardiac disease
Willis, M. S., Bevilacqua, A., Pulinilkunnil, T., Kienesberger, P. C., Tannu, M., & Patterson, C. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.11.008 · Cited by 89
Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 Modulators
Bertamino, A., Soprano, M., Musella, S., Rusciano, M. R., Sala, M., Vernieri, E., Sarno, V. D., Limatola, A., Carotenuto, A., Cosconati, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400311n · Cited by 86
Label-free impedimetric immunosensor for ultrasensitive detection of cancer marker Murine double minute 2 in brain tissue
Elshafey, R., Tlili, C., Abulrob, A., Tavares, A. C., & Zourob, M. M. (2012) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2012.07.049 · Cited by 89
Smurf E3 ubiquitin ligases at the cross roads of oncogenesis and tumor suppression
David, D., Nair, S. A., & Pillai, M. R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.003 · Cited by 89
The p53 Tumor Suppressor Protein Does Not Regulate Expression of Its Own Inhibitor, MDM2, Except under Conditions of Stress
Mendrysa, S. M., & Perry, M. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.6.2023-2030.2000 · Cited by 87
A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85
Mdm2–p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin
Gannon, H. S., Donehower, L. A., Lyle, S., & Jones, S. N. (2011) · Developmental Biology · doi:10.1016/j.ydbio.2011.02.007 · Cited by 87

Authors: Haupt, Y., Maya, R., Kazaz, A., & Oren, M.
Affiliations: Hebrew University of Jerusalem (IL)
Weizmann Institute of Science (IL)
ORCID: Haupt, Ygal
Maya, Ruth
Oren, Moshe
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1997-05
Volume: 387
Issue: 6630
Pages: 296-299
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/387296a0
OpenAlex: W2082979850
Cited by: 4,506
References: 29
Citations by year: 2026: 114 · 2025: 117 · 2024: 136 · 2023: 150 · 2022: 163 · 2021: 167 · 2020: 172 · 2019: 131 · 2018: 128 · 2017: 139 · 2016: 138 · 2015: 122 · 2014: 188 · 2013: 147 · 2012: 197
FWCI: 78.92
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords: MDM2, p53, p53 degradation, protein stabilization, p53-MDM2 interaction, DNA damage response, tumour suppressor, autoregulatory loop, mutant p53
MeSH terms: Animals, HeLa Cells, Humans, Nuclear Proteins, Protein Binding, Proto-Oncogene Proteins, Recombinant Fusion Proteins, RNA, Messenger, Transfection, Tumor Cells, Cultured, Down-Regulation, Tumor Suppressor Protein p53, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mdm2 promotes the rapid degradation of p53

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks